Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Core Insights - Akari Therapeutics is progressing towards becoming a clinical-stage oncology company in 2026, with significant milestones achieved in 2025 [3][4] - The company is developing a novel payload, PH1, for its antibody-drug conjugates (ADCs), which has shown promising preclinical efficacy and safety [4][6] - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and has demonstrated significant activity and prolonged survival in preclinical studies [6] Company Developments - In 2025, Akari established a strategic manufacturing partnership with WuXi Biologics to support clinical readiness [4] - The company plans to initiate its First-in-Human clinical trial for AKTX-101 by late 2026 or early 2027 [6] - Akari is also advancing another ADC candidate, AKTX-102, targeting a novel antigen relevant in gastrointestinal and lung cancers [6] Scientific Innovations - The PH1 payload is designed to disrupt RNA splicing within cancer cells, leading to cancer cell death while activating the immune system [6] - AKTX-101 has the potential for synergy with checkpoint inhibitors, showing prolonged survival both as a single agent and in combination therapies [6] - The PH1 payload has demonstrated activity against cancer cells with key oncogenic drivers such as KRAS, BRAF, and ARV7 [6]